[
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating",
    "summary": "Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data […]",
    "url": "https://finnhub.io/api/news?id=3c667e241ae71857dee56bb2cb74c0bca6221898733823617683ee67c6f8d01d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770542851,
      "headline": "Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating",
      "id": 138391683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is one of the best 52-week low blue-chip stocks to buy right now. Reuters reported on February 4 that Abbott Laboratories (NYSE:ABT) has logged 860 serious injuries tied to the recall of certain FreeStyle Libre 3 and Libre 3 Plus glucose monitoring sensors, based on the U.S. Food and Drug Administration data […]",
      "url": "https://finnhub.io/api/news?id=3c667e241ae71857dee56bb2cb74c0bca6221898733823617683ee67c6f8d01d"
    }
  }
]